Abstract | BACKGROUND: AIMS: To evaluate mood rating, safety and tolerability data from patients with TRD treated with ketamine and the psychoactive control fentanyl, as part of a larger study to explore EEG biomarkers associated with mood response. METHODS: We evaluated the efficacy and safety of intramuscular racemic ketamine in 25 patients with TRD, using a double-blind active-controlled randomized crossover design. Ketamine doses were 0.5 and 1 mg/kg, and the psychoactive control was fentanyl 50 mcg, given at weekly intervals. RESULTS/OUTCOMES: Within 1 h of ketamine dosing, patients reported reduced depression and anxiety ratings, which persisted for up to 7 days. A dose-response profile for ketamine was noted for dissociative side effects, adverse events and changes in blood pressure; however, changes in mood ratings were broadly similar for both ketamine doses. Overall, 14/25 patients (56%) were responders (⩾50% reduction at 24 h compared with baseline) for either ketamine dose for the Hospital Anxiety and Depression Scale ( HADS), and 18/25 (72%) were responders for the HADS-anxiety scale. After fentanyl, only 1/25 ( HADS-depression) and 3/25 ( HADS-anxiety) were responders. Ketamine was generally safe and well tolerated in this population. CONCLUSIONS: Our findings add to the literature confirming ketamine's activity against depressive and anxiety symptoms in patients with TRD.
|
Authors | Paul Glue, Shona Neehoff, Ben Beaglehole, Shabah Shadli, Neil McNaughton, Natalie J Hughes-Medlicott |
Journal | Journal of psychopharmacology (Oxford, England)
(J Psychopharmacol)
Vol. 38
Issue 2
Pg. 162-167
(02 2024)
ISSN: 1461-7285 [Electronic] United States |
PMID | 38293803
(Publication Type: Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Ketamine
- Antidepressive Agents
- Fentanyl
|
Topics |
- Humans
- Ketamine
(adverse effects)
- Depressive Disorder, Major
(drug therapy)
- Cross-Over Studies
- Antidepressive Agents
(adverse effects)
- Depressive Disorder, Treatment-Resistant
(drug therapy)
- Double-Blind Method
- Fentanyl
(adverse effects)
- Depression
(drug therapy)
- Treatment Outcome
|